Biologics Approved In 2012
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA transferred review of most therapeutic biologics to the Center for Drug Evaluation & Research on Oct. 1, 2003. The Center for Biologics Evaluation & Research continues to review other biologics, including vaccines, cellular products, antitoxins and immunoglobulins.
You may also be interested in...
GemVax's Novel Peptide For Alzheimer’s Set To Advance After Positive Phase II
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.
QUOTED. 6 December 2019. Jon Speer.
Medical device regulations that were set in place by the US FDA in the 1990s are evolving with the emergence of digital-health products and their iterative nature, medtech consultant Jon Speer says. Check out his comment here.
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: